Liminatus Pharma, Inc. Approves Significant Bylaw Amendment Reducing Shareholder Meeting Quorum

Key Points:

• Liminatus Pharma, Inc. (NASDAQ: LIMN) Board of Directors approved a critical amendment to the company’s bylaws on February 27, 2026.
• The amendment reduces the quorum requirement for shareholder meetings from a majority to one-third (1/3) of the voting power of the capital stock issued and outstanding and entitled to vote.
• The Board has authorized submission of this Bylaw Amendment for formal ratification by shareholders at the next annual meeting.
• If shareholders do not approve the amendment, the Board retains the authority to maintain it in accordance with Delaware law.
• The amended Bylaws are filed as Exhibit 3.1 to the Form 8-K.

Implications for Shareholders

• This amendment is potentially price-sensitive as it lowers the threshold for holding valid shareholder meetings, possibly making it easier to convene meetings and pass resolutions, including those related to corporate governance, mergers, acquisitions, or other strategic actions.
• Reduced quorum requirements may empower large shareholders or activist investors, as fewer shares are needed to constitute a meeting and influence the outcome of votes.
• Shareholders should carefully assess the impact on their voting power and the potential for shifts in control dynamics at shareholder meetings.
• If not ratified by shareholders, the Board may keep the amendment in force, which could raise questions about governance and shareholder rights.

Emerging Growth Company Status

• Liminatus Pharma, Inc. is classified as an “emerging growth company” under SEC rules.
• The company has NOT elected to use the extended transition period for new or revised financial accounting standards, indicating it will adopt changes more quickly than some peers.

SEC Filing Details and Securities Information

• The Form 8-K was filed on March 4, 2026, and covers the event date of February 27, 2026.
• NASDAQ-listed securities include:
  • Common Stock (Trading Symbol: LIMN)
  • Warrants (Trading Symbol: LIMNW)
• No written communications, soliciting materials, or pre-commencement tender offers were included in the filing.

Additional Details from Amended Bylaws

• Advance notice procedures for nominations and shareholder proposals remain stringent. Stockholders must provide detailed information regarding nominees, proposals, and all related agreements or arrangements.
• Notice of shareholder meetings must specify time, place, means of remote communication, and record dates.
• Inspectors of election will be appointed to verify shares, proxies, and ballots, ensuring procedural integrity.
• Transfer restrictions may apply to shares not registered under the Securities Act.

Potential Impact on Share Price

• The reduction in quorum requirements could facilitate corporate actions and governance changes, which may be viewed positively or negatively by investors depending on context.
• There is a risk of increased influence by minority or activist shareholders if meetings can be held with a smaller percentage of voting power.
• Investors should monitor the upcoming annual meeting for shareholder sentiment and the outcome of the ratification vote.

Disclaimer: This article is intended for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult with qualified professionals before making any investment decisions. The information provided is based on SEC filings and company disclosures as of the dates indicated, and may be subject to change.

View Liminatus Pharma, Inc. Historical chart here